در هنگام جستجو کلمه در قسمت عنوان میتوانید کلمات مورد جستجو را با کاراکتر (-) جدا کنید.
کاربرد نوع شرط:
- جایگاه : پژوهشی
- مجله: Trends in Pharmaceutical Sciences
- نوع مقاله: Journal Article
- کلمات کلیدی:
- چکیده:
- چکیده انگلیسی: Metronidazole is a main stay of modern multidrug therapies for Helicobacter pylori (H. pylori) infection. Metronidazole resistance reduces the effectiveness of these combinations. Various methods have been used for the determination of the sensitivity of H. pylori to metronidazole with conflicting results. The aims of this study were: 1) to compare the E-Test and disk diffusion methods for determining the susceptibility of H. pylori to metronidazole; and 2) Metronidazole resistance in H. pylori has been found to be associated with mutations in rdxA. The role of this gene in metronidazole resistance in H. pylori was examined in this study. A total of 46 H. pylori strains from 223 consecutive patients were examined. The E-Test was performed according to the manufacturer's guidelines, and the disk diffusion according to standard procedure using 5-μg metronidazole disks. DNA was extracted from all H. pylori isolates by boiling & phenol-chloroform methods and then Polymerase Chain Reaction (PCR) was performed. Metronidazole resistance as determined by E-test and disk diffusion methods was 64.3% and 47.6% respectively. None of the resistant or sensitive samples possessed rdxA gene deletion. Disk diffusion method is not reliable in determining metronidazole resistance in H. pylori. An intact rdxA gene has also been reported in metronidazole-resistant H. pylori, suggesting that additional metronidazole resistance mechanisms exist in H. pylori and even molecular methods are not reliable for the detection of resistance.
- انتشار مقاله: 27-07-1394
- نویسندگان: Laleh Mahmoudi,Forough Sharifzadeh,Sarah Mousavi,Bahman Pourabbas,Ramin Niknam
- مشاهده
- جایگاه : پژوهشی
- مجله: International Journal of Hospital Research
- نوع مقاله: Journal Article
- کلمات کلیدی: Surgery,Health care,Antibiotic prophylaxis,Clinical guideline,Medical practice
- چکیده:
- چکیده انگلیسی:
- انتشار مقاله: 15-01-1396
- نویسندگان: Sarah Mousavi,Elham Zamani,Faranak Bahrami
- مشاهده
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: cancer,Clinical trial,fatigue,Bupropion
- چکیده:
- چکیده انگلیسی: Background: Cancer-related fatigue (CRF) is very common and can be experienced at all stages of disease and in
survivors. CRF causes patients more distress than pain or nausea and vomiting. Different pharmacologic interventions
have been evaluated for the management of CRF. The purpose of this study was to determine the efficacy of bupropion
sustained release (SR) as a treatment for fatigue in patients with cancer. Methods: In this randomized, double-blind,
placebo-controlled trial, patients with fatigue due to cancer were randomly assigned to either 150mg daily of bupropion
SR or matching placebo. The primary endpoint was the changes in average daily fatigue from baseline to week 4 using
the Functional Assessment of Chronic Illness-therapy- Fatigue (FACIT-F) questionnaire. Results: 40 patients were
randomly assigned to treatment with bupropion SR or placebo (20 in each group). Analysis of covariance (ANCOVA)
showed a significant improvement in fatigue and quality of life in the bupropion group compared to baseline (P=0.000).
Secondary outcome, including depression, severity of fatigue and performance status didn’t show significant difference
between groups. Generally, bupropion SR was tolerated well. Conclusion: Four weeks of 150 mg bupropion SR
improve fatigue significantly in cancer patients. Bupropion has potential as an effective and safe pharmaceutical agent
for treating CRF.- انتشار مقاله: 10-07-1396
- نویسندگان: Farzaneh Ashrafi,Sarah Mousavi,Mohammad Karimi
- مشاهده